Saraf & Partners, TT&A act on Fortis Healthcare ₹1,770 crore stake acquisition in Agilus Diagnostics

Fortis Healthcare Limited has acquired 31.52% stake in subsidiary Agilus Diagnostics for approximately ₹1,770 crore ($207 million) from three private equity investors - NYLIM Jacob Ballas, Resurgence PE Investments and International Finance Corporation.

Saraf and Partners acted for Fortis Healthcare on all aspects of the transaction.

The transaction team consisted of Vaibhav Kakkar (Senior Partner), Sahil Arora (Partner) and Debarpan Ghosh (Partner).

The Banking and Finance team was led by Rohit Raghavan (Partner); and the competition team was led by Akshayy S Nanda (Partner).

TT&A acted for all three private equity investors – NYLIM Jacob Ballas, Resurgence and IFC, in the transaction.

The transaction team was led by Gautam Saha (Joint Managing Partner) and Punita Gupta (Partner) with assistance from Tanya Maithani (Senior Associate).

Sonam Mathur (Partner) led the competition team with the support of Shubhang Joshi (Managing Associate) and Rishabh Joshi (Associate).

Agilus is a leading Indian company engaged in providing diagnostics services and is a material subsidiary of Fortis Healthcare.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.